Skip to main content

Table 2 Baseline characteristics of the subjects according to follow-up outcomes

From: A longitudinal epidemiological study on the triglyceride and glucose index and the incident nonalcoholic fatty liver disease

Variables Subjects developed NAFLD (n = 1390) Subjects did not develop NAFLD (n = 3149) P
Gender (male/female, n) 1109/281 1887/1262 <  0.001
Age (years) 41.0(34.0–51.0) 41.0 (35.0–51.0) 0.226
BMI (kg/m2) 23.9 (22.2–25.3) 21.5 (19.9–23.3) <  0.001
SBP (mmHg) 122.0 (114.0–131.0) 116.0 (107.0–126.0) <  0.001
DBP (mmHg) 78.0 (72.0–84.0) 74.0 (68.0–80.0) <  0.001
WC (cm) 82.0 (77.0–87.0) 74.0 (69.0–80.0) <  0.001
TyG 8.58 (8.25–8.91) 8.21 (7.91–8.54) <  0.001
BUN (μmol/l) 5.03 (4.23–5.86) 4.95 (4.19–5.75) 0.029
Cr (μmol/l) 75.0 (65.0–83.0) 70.0 (59.0–80.0) <  0.001
FPG (mmol/l) 4.47 (4.15–4.82) 4.43 (4.14–4.77) 0.114
UA (μmol/l) 347.0 (294.0–401.0) 301.0 (245.0–356.0) <  0.001
AST (U/l) 20.0 (17.0–24.0) 19.0 (16.0–22.0) <  0.001
ALT (U/l) 26.0 (19.0–37.0) 19.0 (14.0–26.0) <  0.001
y-GGT (U/l) 21.0 (15.0–33.0) 15.0 (11.0–22.0) <  0.001
TC (mmol/l) 4.77 (4.17–5.41) 4.61 (4.03–5.24) <  0.001
TG (mmol/l) 1.48 (1.10–2.04) 1.03 (0.79–1.39) <  0.001
HDL-C (mmol/l) 1.20 (1.05–1.43) 1.33 (1.10–1.64) <  0.001
LDL-C (mmol/l) 2.73 (2.26–3.26) 2.52 (2.04–3.05) <  0.001
Apo-A1 (g/l) 1.26 (1.11–1.45) 1.35 (1.16–1.53) <  0.001
Apo-B (g/l) 0.95 (0.80–1.14) 0.86 (0.72–1.03) <  0.001
eGFR (ml/(min·1.73 m2)) 108.1 (96.5–121.9) 110.8 (98.4–125.8) <  0.001